Pfizer was founded by German immigrants to the United States 166 years ago, but it is difficult to imagine a company that is more American in character and business practices. An then, on November 23, 2015 it was announced that Pfizer will combine with Allergan in a $160 bn. deal (the largest pharmaceutical transaction ever, and the second-largest one in all history), with the merged company to be...

Recently, H.M. Pharma Consultancy is getting more inquiries concerning our patent reviews: how do we do them? What do I need to do if I want to do the same? Can I join you? Do you have patent reviewer jobs open? To answer the last question first: No, we do not offer employment of this type. But yes, we would be pleased to crowdsource patent analyses. More about this in a future post. The sec...

Thank you for your patience while we migrated this blog to our new website, and prepared new evaluations of drug repurposing patents for publication. Here is the first part of what you will see discussed in the December 2015 Special Issue of ASSAY and Drug Development Technology – a selection of the international drug repurposing patent applications that were published during the second quarter...

When Soviet and Japanese scientists first characterized galantamine in the 1950s, they did not intend it to become a drug for Alzheimer's disease. The early medical uses of this plant alkaloid -- a cholinesterase inhibitor, and (as was found only much later) also a nicotinic acetylcholine receptor modulator – were for paralytic conditions and re-awakening from anesthesia, among others. Re-developm...

H.M. Pharma Consultancy's drug repurposing expertise continues to draw attention. See the recent interview by Pharmtech.com here. Among the high points: our Discontinued Drug and Candidate Database (DDCD) reference tool; the untapped potential of CROs in drug repurposing collaborations; and the business models that we are seeing. In other matters, Mary Ann Liebert, Inc. has re-published the final...

As previously announced, our reviews of international drug repurposing patent applications will be published in the new peer review journal, Drug Repurposing, Rescue, and Repositioning, from now on. At present, reviews for documents published in Q4/2014 are freely available as an Epub ahead of print here. Issue 1(1) of the journal will publish in March 2015.

And have we got news for you! Several readers of this blog have wondered why we did not continue our constant stream of drug repurposing patent evaluations during the past three months. Well, besides being very busy with our Discontinued Drug and Candidate Database (DDCD) - which we believe will eventually become an extremely valuable resource for drug repurposing - we have submitted several ma...

The inaugural "zero" issue of the Mary Ann Liebert, Inc. peer review journal Drug Repurposing, Rescue and Repositioninghas been much applauded and we are now putting out a call for manuscripts to be published in the first regular issue 1(1), due in early 2015. We will need your contributions by December 26, 2014 at the latest. Meanwhile, be invited to the first part of our PCT drug repurposing pa...